Allogene Therapeutics Inc. [ALLO] Stock trading around $8.50 per share: What’s Next?


Allogene Therapeutics Inc. [NASDAQ: ALLO] gained 1.31% or 0.11 points to close at $8.50 with a heavy trading volume of 3292994 shares. The company report on April 28, 2022 that Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


New Position Aimed at Attracting, Retaining, and Cultivating a Best-in-Class Workforce as Allogene Scales its Operations for its Next Stage of Growth.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Susan Lundeen as Chief People Officer effective May 2, 2022. In this newly created role, Susan will oversee Allogene’s Human Resources efforts as the Company continues to advance a rapidly growing AlloCAR T pipeline.

It opened the trading session at $8.47, the shares rose to $8.62 and dropped to $7.94, the range by which the price of stock traded the whole day. The daily chart for ALLO points out that the company has recorded -46.68% loss over the past six months. However, it is still -13.64% lower than its most recent low trading price.

If we look at the average trading volume of 1.60M shares, ALLO reached to a volume of 3292994 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Allogene Therapeutics Inc. [ALLO]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALLO shares is $29.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALLO stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

B. Riley Securities have made an estimate for Allogene Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 28, 2022. While these analysts kept the previous recommendation, Cowen raised their target price to Outperform. The new note on the price target was released on October 20, 2021, representing the official price target for Allogene Therapeutics Inc. stock. Previously, the target price had yet another drop from $44 to $18, while Stifel kept a Hold rating on ALLO stock. On October 08, 2021, analysts decreased their price target for ALLO shares from 71 to 20.

The Average True Range (ATR) for Allogene Therapeutics Inc. is set at 0.55, with the Price to Sales ratio for ALLO stock in the period of the last 12 months amounting to 32.00. The Price to Book ratio for the last quarter was 1.29, with the Price to Cash per share for the same quarter was set at 3.15.

Trading performance analysis for ALLO stock

Allogene Therapeutics Inc. [ALLO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.70. With this latest performance, ALLO shares dropped by -15.34% in over the last four-week period, additionally sinking by -46.68% over the last 6 months – not to mention a drop of -73.42% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALLO stock in for the last two-week period is set at 47.72, with the RSI for the last a single of trading hit 51.13, and the three-weeks RSI is set at 45.92 for Allogene Therapeutics Inc. [ALLO]. The present Moving Average for the last 50 days of trading for this stock 8.88, while it was recorded at 8.29 for the last single week of trading, and 16.20 for the last 200 days.

Allogene Therapeutics Inc. [ALLO]: A deeper dive into fundamental analysis

Allogene Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.80 and a Current Ratio set at 9.80.

Allogene Therapeutics Inc. [ALLO]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALLO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Allogene Therapeutics Inc. go to 1.00%.

An analysis of insider ownership at Allogene Therapeutics Inc. [ALLO]

There are presently around $890 million, or 61.90% of ALLO stock, in the hands of institutional investors. The top three institutional holders of ALLO stocks are: TPG GP A, LLC with ownership of 18,716,306, which is approximately New of the company’s market cap and around 3.20% of the total institutional ownership; TPG GROUP HOLDINGS (SBS) ADVISORS, INC., holding 18,716,306 shares of the stock with an approximate value of $159.09 million in ALLO stocks shares; and VANGUARD GROUP INC, currently with $57.31 million in ALLO stock with ownership of nearly 0.689% of the company’s market capitalization.

102 institutional holders increased their position in Allogene Therapeutics Inc. [NASDAQ:ALLO] by around 32,171,768 shares. Additionally, 73 investors decreased positions by around 16,536,550 shares, while 35 investors held positions by with 55,942,876 shares. The mentioned changes placed institutional holdings at 104,651,194 shares, according to the latest SEC report filing. ALLO stock had 39 new institutional investments in for a total of 22,076,342 shares, while 29 institutional investors sold positions of 7,166,820 shares during the same period.